A Safety and Efficacy Study of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

Lichen Planus Clinical Trial

Official title:

A Randomized, Double-Blind, Placebo-Controlled Pilot Study of the Efficacy and Safety of Alefacept in the Treatment of Moderate to Severe Erosive Mucosal Lichen Planus

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00135733
• Other study ID #: 2004P002141
• Status: Terminated
• Phase: Phase 2
• First received: August 24, 2005
• Last updated: February 10, 2009
• Start date: April 2004
• Est. completion date: December 2004

Study information

• Verified date: February 2009
• Source: Massachusetts General Hospital
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to find out how safe and effective an investigational drug called alefacept (amevive) is for the treatment of moderate to severe erosive mucosal lichen planus.

Lichen planus is a skin disease that can last a long time and cause significant pain, itching, and scarring. It can affect the mucous membranes (area inside the mouth and vagina) and these areas can become erosive (sores can develop). Currently there is no known cure for this disease.

An investigational drug is one that has not been approved by the United States (US) Food and Drug Administration (FDA) to treat a particular condition or disease. Alefacept has been approved to treat psoriasis (a scaly skin rash). A number of reports suggest that lichen planus develops for some of the same reasons as psoriasis, but alefacept is not yet approved for the treatment of psoriasis.

Description:

Lichen planus is an inflammatory disorder that affects skin, mucous membranes (the skin in the mouth and vagina), nails, and hair. It is thought that T-cells (cells that help fight infection) become activated and multiply faster than normal and that this contributes to the development of the skin sores.

Alefacept works by slowing the rate at which T-cells become activated and helps to decrease the number of T-cells. By blocking the activity and decreasing the number of T-cells Alefacept may help improve the disease and decrease the sores on the skin.

Participants in this study will be randomly assigned to receive either alefacept or a placebo. A placebo looks just like the study drug but contains no active medication. Placebos help study doctors find out if the effects of the study drug are due to the drug itself or just because of being in the study. This type of study design helps measure the true effectiveness of a treatment. Participants have a 1 out of 2 chance of receiving alefacept and a 1 out of 2 chance of receiving placebo. Neither participants nor the study doctors will know which group participants have been assigned to.

The researchers expect to enroll 26 subjects in this study at research sites in the U.S. About 16 subjects will be enrolled at Brigham and Women's Hospital and Massachusetts General Hospital.

Biogen Idec., Inc. is the maker of alefacept and is the sponsor of this study.

If taking part in another research study or have taken part in a research study in the last 28 days, individuals will not be able to take part in this study. Patients cannot be on multiple studies simultaneously; however, exceptions are made for non-invasive, non-interventional, and observational studies.

This study will last 24 weeks, with a total of 16 visits; screening week 0 (baseline), weeks 1-12, week 16 and week 24. Participants will not be allowed to use any oral or injectable medications for lichen planus during this study. Participants also will not be allowed to use certain creams for lichen planus during the study. The study consists of weekly injections of the medication for 12 weeks and then a 12 week follow up period.

All participants must be at least 18 years of age with a diagnosis of moderate to severe mucosal lichen planus. Neither pregnant nor nursing women will be included in the study.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 13
• Est. completion date: December 2004
• Est. primary completion date: December 2004
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years and older

Eligibility

Key Inclusion Criteria:

• Written informed consent, authorize release and use of protected health information

• At least 18 years of age

• Diagnosis of moderate to severe mucosal lichen planus

• No systemic (oral or injectable) treatment of lichen planus for 4 weeks prior to starting study drug.

• Willing to forgo changes in topical treatment (creams) for 4 weeks before receiving the study drug and during the course of the study.

• Off of topical tacrolimus or pimecrolimus for 4 weeks prior to starting the study drug

• CD4+ T lymphocyte counts must be above the lower limit of normal laboratory value

Key Exclusion Criteria:

• Clinically significant abnormal laboratory values

• Skin lesions currently undiagnosed, but suspicious for malignancy

• Other skin disease that might interfere with lichen planus status assessments.

• History of malignancy other than basal cell carcinomas or fewer than 3 squamous cell carcinomas

• Exposure to systemic therapy for lichen planus within 4 weeks prior to enrollment.

• Previous exposure to alefacept

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lichen Planus

Intervention

Drug:
• Amevive (Alefacept)

• Placebo

Locations

Country	Name	City	State
United States	Clinical Unit for Research Trials in Skin	Boston	Massachusetts

Sponsors (4)

Lead Sponsor	Collaborator
Massachusetts General Hospital	Biogen, Brigham and Women's Hospital, Stanford University

Country where clinical trial is conducted

United States, 

References & Publications (2)

Daoud MS, Pittelkow MR, Fitzpatrick's Dermatology in General Medicine, sixth edition, ed. Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, McGraw-Hill, pp 463-476, 2003.

Stewart EG, Vulvar Lichen Planus, Up To Date, version 12.3, Aug 2004.

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Statistically significant changes in pain level
Primary	Statistically significant changes in appearance of lesions (sores)
Secondary	Statistically significant changes in severity of itching
Secondary	Statistically significant changes in redness, amount of body surface area involved, number of sores, and or depth of involvement
Secondary	Statistically significant changes in quality of life

External Links

•   CURTIS website